Company	Compound	Phase	Indication & Inclusion Criteria	Locations	Clinical Trial
Exon Skipping					
NS Pharma Nippon Shinyaku	NS-089/ NCNP-02	Phase II	Duchenne Muscular Dystrophy 4 years to 14 years Ambulatory Amenable to exon 44 skipping	USA (CO, FL, GA, IL, KS, OH, PA, TX, VA) CAN, JPN, KOR	NCT05996003
NS Pharma Nippon Shinyaku	NS-050/ NCNP-03	Phase I & II	Duchenne Muscular Dystrophy 4 years to 14 years Ambulatory Amenable to exon 50 skipping	USA (CA, CO, IL, KS, PA) CAN, JPN, KOR, TUR	NCT06053814 (Meteor50)
Entrada	ELEVATE-44-201	Phase I & II	Duchenne Muscular Dystrophy 4 years to 20 years Ambulatory Amenable to exon 44 skipping	BEL, ITA, ESP, GBR	NCT07037862 (ELEVATE-44)
Entrada	ELEVATE-45-201	Phase I & II	Duchenne Muscular Dystrophy 4 years to 20 years Ambulatory Amenable to exon 45 skipping	BEL, ITA, NLD, ESP, GBR	NCT07038824 (ELEVATE-45)
BioMarin Pharmaceutical	BMN 351	Phase I & II	Duchenne Muscular Dystrophy 4 years to 10 years Ambulatory Amenable to exon 51 skipping	ITA, NLD, ESP, GBR, TUR	NCT06280209
Gene Therapy					
REGENXBIO	RGX-202	Phase II & III	Duchenne Muscular Dystrophy 1 Year and older Ambulatory Mutation in Exons 18 and above	USA (AR, CA, CO, GA, IL, IA, MA, OR, TX, VA) CAN	NCT05693142 (AFFINITY DUCHENNE)
Solid Biosciences	SGT-003	Phase I & II	Duchenne Muscular Dystrophy 4 Years to 8 Years Ambulatory	USA (AR, CA, GA, MO, OH, VA) CAN, ITA	NCT06138639 (INSPIRE DUCHENNE)
Insmed	INS1201	Phase I	Duchenne Muscular Dystrophy 2 Years to 4 Years Ambulatory Mutation between Exons 18 and 58	USA (AR, CA, GA, TN)	NCT06817382 (ASCEND)
Sarepta	Gene Therapy long-term follow-up	Phase IV	Duchenne Muscular Dystrophy Patients have been prescribed delandistrogene moxeparvovec	USA (AR, CO, DC, FL, IL, IN, KS, MI, PA, TN, TX, VA, WI)	NCT06270719 (ENDURE)

Sarepta	SRP-9001 (Delandistrogene Moxeparvovec)	Phase I	Duchenne Muscular Dystrophy Patients with pre-existing AAV Abs 4 Years to 8 Years	USA(FL, MO, OH)	NCT06597656 (HORIZON)
Roche	Delandistrogene Moxeparvovec	Phase II	Duchenne Muscular Dystrophy Up to 3 Years Mutation between Exons 18 and 79	BEL, DEU, FRA, ITA, ESP, GBR	NCT06128564 (ENVOL)
HuidaGene Therapeutics	HG30201	NA	Duchenne Muscular Dystrophy 4 Years to 8 Years Ambulatory Mutation in Exons 52, 52-61, or 52-63	CHN	NCT06594094 (MUSCLE)
Anti-inflammatory					
Nationwide Children's Hospital Children's Hospital of Chicago Children's Hospital Medical Center, Cincinnati	Prednisolone	Phase IV	Duchenne Muscular Dystrophy 1 Month to 30 Months	USA (IL, OH, TX)	NCT05412394
Others					
Italfarmaco	Givinostat	Phase III	Duchenne Muscular Dystrophy Years 9 to 17 years Non-ambulant	BEL, CAN, FRA, DEU, ITA, NLD, GBR	NCT05933057 (ULYSSES)
Sqy Therapeutics	SQY51	Phase I & IIa	Duchenne Muscular Dystrophy 6 Years and older ≥ 16 kg body weight Amenable to exon-51 skipping	FRA	NCT05753462 (AVANCE1)
Roche	Satralizumab	Phase II	Duchenne Muscular Dystrophy 8 Years to 15 Years Additional criteria for fracture-naïve and low-trauma fractures participants	USA (AR, GA, MA, MI, NY, TX, VA) ITA, POL, ESP	NCT06450639 (SHIELD DMD)
Sardocor Corp/Medera	SRD-001 (AAV1/SERCA2a)	Phase Ib	Duchenne Muscular Dystrophy 18 Years and older	USA(KS, OH)	NCT06224660 (MUSIC-DMD)
Medical University of Gdansk	Metoprolol Succinate	Phase III	Duchenne Muscular Dystrophy 8 Years to 17 Years	POL	NCT05066633